quit sandbagging vbroker - gotta be worth $20-$25 at this point
they're one of the big boys, would be great to see them come out with a BUY recommendation and target, could be the jolt we need to send us higher
1. Start of Phase II Oxi4503 trial in AML / MDS
2. Overall survival of GOG186i trial in Ovarian
3. Data from GI Nets Phase II trial
4. Data from Phase II PAZOFOS trial in Ovarian
5. Expansion of GI Nets trial into P Nets
6. SPA acceptance for Phase III Ovarian trial
7. Some guidance on the pre clinical assets and Phase I
Plus the potential start of a Glioblastoma trial by early 2016??
... and we trade at cash ....
That the reults of GI NETS are positive, it's 'open label'. For those non science types it means the Docs know who is receiving the drug and are not 'blinded'. They are measuring Biomarkers not survival so they can see that patients getting the drug have lower Biomarkers after starting treatment. The trial is showing success, that's why they are expanding it into "P" Nets (pancreatic). Schweity also said they have early efficacy results from Oxi4503 in AML. We have winning drugs here GIRLZ!